Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 3.93
SNSS's Cash to Debt is ranked lower than
64% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. SNSS: 3.93 )
Ranked among companies with meaningful Cash to Debt only.
SNSS' s Cash to Debt Range Over the Past 10 Years
Min: 2.18  Med: 22.08 Max: No Debt
Current: 3.93
Equity to Asset 0.39
SNSS's Equity to Asset is ranked lower than
78% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SNSS: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
SNSS' s Equity to Asset Range Over the Past 10 Years
Min: -3.31  Med: 0.55 Max: 0.89
Current: 0.39
-3.31
0.89
F-Score: 2
Z-Score: -24.65
M-Score: -3.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1190.02
SNSS's Operating margin (%) is ranked lower than
79% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. SNSS: -1190.02 )
Ranked among companies with meaningful Operating margin (%) only.
SNSS' s Operating margin (%) Range Over the Past 10 Years
Min: -64863.64  Med: -513.17 Max: -169.03
Current: -1190.02
-64863.64
-169.03
Net-margin (%) -803.80
SNSS's Net-margin (%) is ranked lower than
76% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. SNSS: -803.80 )
Ranked among companies with meaningful Net-margin (%) only.
SNSS' s Net-margin (%) Range Over the Past 10 Years
Min: -74506.06  Med: -560.67 Max: -166.44
Current: -803.8
-74506.06
-166.44
ROE (%) -208.21
SNSS's ROE (%) is ranked lower than
92% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. SNSS: -208.21 )
Ranked among companies with meaningful ROE (%) only.
SNSS' s ROE (%) Range Over the Past 10 Years
Min: -1585.52  Med: -155.31 Max: -57.33
Current: -208.21
-1585.52
-57.33
ROA (%) -64.87
SNSS's ROA (%) is ranked lower than
77% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. SNSS: -64.87 )
Ranked among companies with meaningful ROA (%) only.
SNSS' s ROA (%) Range Over the Past 10 Years
Min: -448.13  Med: -68.61 Max: -39.99
Current: -64.87
-448.13
-39.99
ROC (Joel Greenblatt) (%) -78410.49
SNSS's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. SNSS: -78410.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNSS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -127024.62  Med: -8675.79 Max: -698.52
Current: -78410.49
-127024.62
-698.52
Revenue Growth (3Y)(%) -6.50
SNSS's Revenue Growth (3Y)(%) is ranked lower than
60% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SNSS: -6.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNSS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -51.30 Max: 74.5
Current: -6.5
0
74.5
EBITDA Growth (3Y)(%) 15.90
SNSS's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. SNSS: 15.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNSS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.5  Med: -35.70 Max: 15.9
Current: 15.9
-59.5
15.9
EPS Growth (3Y)(%) 18.20
SNSS's EPS Growth (3Y)(%) is ranked higher than
76% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SNSS: 18.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNSS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.4  Med: -48.40 Max: 20.4
Current: 18.2
-60.4
20.4
» SNSS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SNSS Guru Trades in Q3 2014

Jim Simons Sold Out
Steven Cohen Sold Out
First Eagle Investment Sold Out
» More
Q4 2014

SNSS Guru Trades in Q4 2014

Paul Tudor Jones 17,516 sh (New)
First Eagle Investment 1,414,276 sh (New)
» More
Q1 2015

SNSS Guru Trades in Q1 2015

Paul Tudor Jones Sold Out
First Eagle Investment 587,976 sh (-58.43%)
» More
Q2 2015

SNSS Guru Trades in Q2 2015

First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.12
SNSS's P/B is ranked lower than
74% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. SNSS: 4.12 )
Ranked among companies with meaningful P/B only.
SNSS' s P/B Range Over the Past 10 Years
Min: 1.01  Med: 2.75 Max: 297.5
Current: 4.12
1.01
297.5
P/S 14.25
SNSS's P/S is ranked lower than
64% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. SNSS: 14.25 )
Ranked among companies with meaningful P/S only.
SNSS' s P/S Range Over the Past 10 Years
Min: 0.9  Med: 10.95 Max: 157.25
Current: 14.25
0.9
157.25
Current Ratio 1.94
SNSS's Current Ratio is ranked lower than
76% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. SNSS: 1.94 )
Ranked among companies with meaningful Current Ratio only.
SNSS' s Current Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.91 Max: 12.17
Current: 1.94
0.71
12.17
Quick Ratio 1.94
SNSS's Quick Ratio is ranked lower than
71% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SNSS: 1.94 )
Ranked among companies with meaningful Quick Ratio only.
SNSS' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 2.91 Max: 12.17
Current: 1.94
0.71
12.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.67
SNSS's Price/Net Cash is ranked higher than
66% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: 5.77 vs. SNSS: 4.67 )
Ranked among companies with meaningful Price/Net Cash only.
SNSS' s Price/Net Cash Range Over the Past 10 Years
Min: 1.68  Med: 3.31 Max: 178.5
Current: 4.67
1.68
178.5
Price/Net Current Asset Value 4.38
SNSS's Price/Net Current Asset Value is ranked higher than
67% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. SNSS: 4.38 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SNSS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.62  Med: 3.07 Max: 273.5
Current: 4.38
1.62
273.5
Price/Tangible Book 4.38
SNSS's Price/Tangible Book is ranked higher than
58% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SNSS: 4.38 )
Ranked among companies with meaningful Price/Tangible Book only.
SNSS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.6  Med: 2.74 Max: 273.5
Current: 4.38
1.6
273.5
Price/Median PS Value 1.59
SNSS's Price/Median PS Value is ranked lower than
55% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. SNSS: 1.59 )
Ranked among companies with meaningful Price/Median PS Value only.
SNSS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 1.05 Max: 13.09
Current: 1.59
0.09
13.09
Earnings Yield (Greenblatt) (%) -94.55
SNSS's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. SNSS: -94.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNSS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -84.83  Med: 45.80 Max: 16068
Current: -94.55
-84.83
16068

More Statistics

Revenue(Mil) $3
EPS $ -0.39
Beta1.34
Short Percentage of Float1.57%
52-Week Range $0.65 - 3.72
Shares Outstanding(Mil)75.47

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 3 3 9
EPS($) -0.45 -0.43 -0.38
EPS without NRI($) -0.45 -0.43 -0.38

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RYIN.Germany,
Sunesis Pharmaceuticals Inc was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is an anti-cancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. In October 2014, the Company announced the results of a Phase 3, multi-national, randomized, double-blind, placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial, which enrolled 711 adult patients, was designed to evaluate the effect of vosaroxin in combination with cytarabine, most commonly used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine, and was conducted at 124 study sites in the U.S., Canada, Europe, South Korea, Australia and New Zealand. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.
» More Articles for SNSS

Headlines

Articles On GuruFocus.com
Roundys Among Largest Insiders' Buys of the Week Dec 31 2015 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Weekly CFO Buys Highlight: SNSS, INUV, CEP, CMTL, SURW Oct 09 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 
Most Trade Guru Stocks: Citigroup Inc., Bank of America Corp., Alcoa Inc., Sunesis Pharmaceuticals Dec 12 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 28 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Edited Transcript of SNSS earnings conference call or presentation 5-Nov-15 4:00pm GMT Jan 08 2016
Sunesis Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization... Jan 04 2016
Sunesis Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization... Jan 04 2016
Will Sunesis Pharmaceuticals (SNSS) Continue to Surge Higher? Dec 24 2015
Sunesis Announces Closing of $26 Million Offering of Securities and Exercise of Underwriter’s... Dec 21 2015
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 21 2015
Sunesis Announces Closing of $26 Million Offering of Securities and Exercise of Underwriter’s... Dec 21 2015
Sunesis Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 17 2015
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Dec 16 2015
Sunesis Announces Pricing of $25 Million Offering of Securities Dec 16 2015
Sunesis Announces Pricing of $25 Million Offering of Securities Dec 16 2015
SUNESIS PHARMACEUTICALS INC Financials Dec 08 2015
Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin... Dec 08 2015
Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin... Dec 08 2015
Sunesis Pharmaceuticals Announces Presentation of Positive Results From MD Anderson Sponsored Trial... Dec 07 2015
Sunesis Pharmaceuticals Announces Presentation of Positive Results From MD Anderson Sponsored Trial... Dec 07 2015
Sunesis Pharmaceuticals Announces Presentation of Results From Washington University Sponsored Phase... Dec 06 2015
Sunesis Pharmaceuticals Announces Presentation of Results From Washington University Sponsored Phase... Dec 06 2015
Sunesis Partners With Clinigen Group to Initiate a Compassionate Use Program for Patients With... Dec 03 2015
Sunesis Partners With Clinigen Group to Initiate a Compassionate Use Program for Patients With... Dec 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK